Clinical trial
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
NCT00082875 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00082875 |
|---|---|
| Title | Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma |
| Official title | A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage III Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | cilengitide, pharmacological study, laboratory biomarker analysis |
| Enrollment | 56 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | May 19, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: